Hong Kong: Global Cord Blood Corp enters cell therapy market via Cellenkos acquisition

NYSE listed, Global Cord Blood Corporation (GCBC), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is acquiring 100% of Cellenkos (CLNK) and the rights to develop and commercialize its existing and future products other than those related to its existing collaboration with Incyte Corporation. CLNK…

You must be a HMI Subscriber to view this content.

Subscribe Now »